by Kristen Markus | Aug 13, 2021 | Clinical trial, Evidence generation, Health outcomes, Market access, Medical affairs
Insights Evidence generation and communication in drug development Clinical evidence generation: clinical trials Health researchers continually discover new evidence that deepens our understanding of disease processes and progression. This rapidly evolving knowledge...
by Kristen Markus | Aug 13, 2021 | Evidence synthesis, Health outcomes, Healthcare, Market access
Insights Evidence synthesis for healthcare decision-making What is evidence synthesis? As the pharmaceutical market rapidly evolves to keep pace with patient needs and emerging research, healthcare decision makers must continuously re-evaluate the evidence base that...
by Anna Pagotto | Jul 6, 2021 | Market access, NICE, Oncology
Insights Market access for immuno-oncology (I-O) therapies in the UK The rapid development of immuno-oncology (I-O) therapies has transformed the cancer treatment landscape, but health technology assessment (HTA) agencies can decide against covering or reimbursing...
